• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC14D9C filed by Vector Group Ltd.

    8/23/24 10:54:57 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $VGR alert in real time by email
    SC14D9C 1 d870097dsc14d9c.htm SC14D9C SC14D9C

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14D-9

    SOLICITATION/RECOMMENDATION STATEMENT

    UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

     

     

    VECTOR GROUP LTD.

    (Name of Subject Company)

     

     

    VECTOR GROUP LTD.

    (Name of Person(s) Filing Statement)

     

     

    Common stock, par value $0.10 per share

    (Title of Class of Securities)

    92240M108

    (CUSIP Number of Class of Securities)

    Howard M. Lorber

    President and Chief Executive Officer

    Vector Group Ltd.

    4400 Biscayne Boulevard,

    Miami, Florida 33137

    (305) 579-8000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of the Person(s) Filing Statement)

    With copies to:

    Alison R. Ressler

    Alan Fishman

    Sullivan & Cromwell LLP

    125 Broad Street

    New York, New York 10004

    (212) 558-4000

     

     

     

    ☒

    Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

     

     


    This Schedule 14D-9 filing consists of certain communications relating to the proposed acquisition of Vector Group Ltd., a Delaware corporation (the “Company”), by JTI (US) Holding Inc., a Delaware corporation (“Parent”), and Vapor Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), pursuant to the terms and subject to the conditions of an Agreement and Plan of Merger, dated as of August 21, 2024, by and among the Company, Parent and Merger Sub.

     

    1.    Exhibit 99.1: Email from Nick Anson, President and Chief Operating Officer of Liggett Vector Brands LLC (“Liggett”) and Ron Bernstein, Non-Executive Chairman and Senior Advisor of Liggett, sent to Liggett’s employees, dated August 21, 2024.
    2.    Exhibit 99.2: Email from Howard Lorber, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated August 21, 2024.
    3.    Exhibit 99.3: Email from Nick Anson, President and Chief Operating Officer of Liggett, sent to Liggett’s customers, dated August 21, 2024.
    4.    Exhibit 99.4: Liggett Employee Fact Sheet.

    Items #1 - 4 listed above were first used or made available on August 21, 2024.

    The information set forth under Items 1.01, 5.02, 7.01 and 9.01 of the Current Report on Form 8-K filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on August 21, 2024 (including all exhibits attached thereto) is incorporated herein by reference.

    ADDITIONAL INFORMATION AND WHERE TO FIND IT

    The tender offer described in this communication has not yet commenced. This communication is neither an offer to purchase nor a solicitation of an offer to sell shares of the Company. At the time the offer is commenced, Parent and its merger subsidiary, Merger Sub, will file a Tender Offer Statement on Schedule TO with the SEC, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. The Company stockholders and other investors are urged to read the tender offer materials (including an Offer to Purchase, a related Letter of Transmittal and certain other offer documents) and the Solicitation/Recommendation Statement, as they may be amended from time to time, when they become available because they will contain important information that should be read carefully before any decision is made with respect to the tender offer. These materials will be sent free of charge to all stockholders of the Company In addition, all of these materials (and all other materials filed by the Company with the SEC) will be available at no charge from the SEC through its website at www.sec.gov. Investors and security holders may also obtain free copies of the documents filed with the SEC by the Company at www.vectorgroupltd.com.

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This communication includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, may be forward-looking statements. These forward-looking statements may be accompanied by such words as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “project,” “target,” “should,” “likely,” “will” and other words and terms of similar meaning. Forward-looking statements include, among other things, statements regarding


    the potential benefits of the proposed transaction; the prospective performance, future plans, events, expectations, performance, objectives and opportunities and the outlook for the Company’s business; filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to complete the transaction considering the various closing conditions; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

    Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; the risk that the proposed transaction may not be completed in a timely manner or at all; uncertainties as to how many of the Company’s stockholders will tender their stock in the offer; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effect of this announcement or pendency of the proposed transaction on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its business generally or its stock price; risks related to diverting management’s attention from the Company’s ongoing business operations; the risk that stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification and liability; other business effects, including the effects of industry, economic or political conditions outside of the Company’s control; transaction costs; and other risks and uncertainties detailed from time to time in documents filed with the SEC by the Company, including the Company’s current annual report on Form 10-K on file with the SEC, as well as the Schedule 14D-9 to be filed by the Company and the tender offer documents to be filed by Parent and Merger Sub.

    The Company is providing the information in this filing as of this date and assumes no obligation to update any forward-looking statements as a result of new information, future developments or otherwise, except as required by law.

     

    Exhibit
    No.
      

    Description

    99.1    Email from Nick Anson, President and Chief Operating Officer of Liggett and Ron Bernstein, Non-Executive Chairman and Senior Advisor of Liggett, sent to Liggett’s employees, dated August  21, 2024.
    99.2    Email from Howard Lorber, President and Chief Executive Officer of the Company, sent to the Company’s employees, dated August 21, 2024.
    99.3    Email from Nick Anson, President and Chief Operating Officer of Liggett, sent to Liggett’s customers, dated August 21, 2024.
    99.4    Liggett Employee Fact Sheet.
    Get the next $VGR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VGR

    DatePrice TargetRatingAnalyst
    3/31/2022$12.00 → $16.00Equal Weight → Overweight
    Barclays
    11/15/2021$13.00 → $17.00Underweight → Equal Weight
    Barclays
    11/9/2021$18.00Perform → Outperform
    Oppenheimer
    9/13/2021$15.00 → $13.00Equal Weight → Underweight
    Barclays
    More analyst ratings

    $VGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Watkins Barry returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

    4 - VECTOR GROUP LTD (0000059440) (Issuer)

    10/7/24 9:41:06 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Bell Marc N was granted 164,500 shares and returned $5,100,000 worth of shares to the company (340,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

    4 - VECTOR GROUP LTD (0000059440) (Issuer)

    10/7/24 9:14:02 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Sharpe Jean E returned $225,000 worth of shares to the company (15,000 units at $15.00), closing all direct ownership in the company (SEC Form 4)

    4 - VECTOR GROUP LTD (0000059440) (Issuer)

    10/7/24 9:08:43 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    $VGR
    SEC Filings

    View All

    SEC Form 15-12G filed by Vector Group Ltd.

    15-12G - VECTOR GROUP LTD (0000059440) (Filer)

    10/17/24 8:00:07 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Vector Group Ltd.

    EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

    10/8/24 12:15:04 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form EFFECT filed by Vector Group Ltd.

    EFFECT - VECTOR GROUP LTD (0000059440) (Filer)

    10/8/24 12:15:08 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    $VGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $VGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hims & Hers Health Set to Join S&P SmallCap 600

    NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

    10/4/24 6:05:00 PM ET
    $HIMS
    $SPGI
    $VGR
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Vector Group Announces Agreement to be Acquired by JT Group

    Delivers significant value for stockholders while positioning Vector Group for long-term success Vector Group Ltd. (NYSE:VGR) today announced that it has entered into a definitive agreement to be acquired by JT Group, a global company headquartered in Tokyo, Japan, operating in tobacco, pharmaceuticals and processed food. JT Group's global tobacco business, headquartered in Geneva, Switzerland, manufactures and sells some of the world's best-known brands in over 130 markets worldwide – including Winston and Camel (outside the U.S.), as well as MEVIUS and LD. Under the terms of the agreement, JT Group will offer to acquire all outstanding shares of Vector Group common stock for $15.00 pe

    8/21/24 6:00:00 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Group Declares Quarterly Cash Dividend

    Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

    8/20/24 3:08:00 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Grp upgraded by Barclays with a new price target

    Barclays upgraded Vector Grp from Equal Weight to Overweight and set a new price target of $16.00 from $12.00 previously

    3/31/22 7:41:06 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Grp upgraded by Barclays with a new price target

    Barclays upgraded Vector Grp from Underweight to Equal Weight and set a new price target of $17.00 from $13.00 previously

    11/15/21 8:00:05 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Group upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Vector Group from Perform to Outperform and set a new price target of $18.00

    11/9/21 6:13:20 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    $VGR
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Health Set to Join S&P SmallCap 600

    NEW YORK, Oct. 4, 2024 /PRNewswire/ -- Hims & Hers Health, Inc. (NYSE:HIMS) will replace Vector Group Ltd (NYSE:VGR) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, October 9. JT Group is acquiring Vector Group in a deal expected to close soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector October 9, 2024 S&P SmallCap 600 Addition Hims & Hers Health HIMS Health Care S&P SmallCap 600 Deletion Vector Group VGR Consumer Staples For more information about S&P Dow Jones Indices, please visit www.spdji.com

    10/4/24 6:05:00 PM ET
    $HIMS
    $SPGI
    $VGR
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Douglas Elliman Appoints Richard Ferrari as President and CEO of Brokerage for New York City and the Northeast Region

    Yuval Greenblatt and Alfred Renna Promoted to Senior Managing Director of Operations and Senior Managing Director of Sales, Respectively, for Flagship 575 Madison Avenue Office Douglas Elliman, one of the largest residential real estate brokerages in the United States, announced today that real estate veteran Richard Ferrari has joined the firm as President and CEO of Brokerage for New York City and the Northeast Region. In this role, Ferrari, a highly regarded industry expert, will oversee the firm's New York City resale markets, including Manhattan, Brooklyn, Riverdale and Long Island City in Queens. He will also assume responsibility for Elliman's New Jersey, Westchester, Connecticut a

    7/21/21 8:30:00 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Group Appoints Technology Veteran Wilson L. White to its Board of Directors

    Expands Board to 10 Directors with Addition of Silicon Valley Executive Vector Group Ltd. (NYSE:VGR) (the "Company") today announced that it has appointed technology industry veteran, Wilson L. White, to its Board of Directors, effective immediately. Mr. White currently serves as Senior Director of Government Affairs and Public Policy at Google. With Mr. White's appointment, Vector Group's Board expands to 10 directors. "With many years of experience in the technology industry, including government relations and legal expertise, Wilson brings to the Board a unique skillset that will further strengthen Vector Group's commitment to staying at the forefront of our business' rapidly-evolving

    6/22/21 8:00:00 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    $VGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

    SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

    10/15/24 4:00:16 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

    SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

    10/7/24 8:43:24 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vector Group Ltd.

    SC 13D/A - VECTOR GROUP LTD (0000059440) (Subject)

    10/1/24 4:27:47 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    $VGR
    Financials

    Live finance-specific insights

    View All

    Vector Group Declares Quarterly Cash Dividend

    Vector Group Ltd. (NYSE:VGR) today announced that its Board of Directors has declared a regular quarterly cash dividend on its common stock of $0.20 per share. The quarterly cash dividend will be payable on September 12, 2024, to holders of record as of August 30, 2024. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20240819252290/en/

    8/20/24 3:08:00 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Group Reports Second Quarter 2024 Financial Results

    Montego maintains position as largest discount brand in the U.S. Second Quarter 2024 Highlights: Consolidated revenues of $371.9 million, up 1.7% or $6.3 million compared to the prior year period. Tobacco segment wholesale market share increased to 5.7% from 5.4% in the prior year period and retail market share remained at 5.8%, unchanged from the prior year period. Montego wholesale and retail market share both increased to 4.1% from 3.4% and 3.5%, respectively, in the prior year period. Operating income of $97.8 million, up 36.5% or $26.1 million compared to the prior year period. Tobacco segment operating income of $102.9 million, up 37.0% or $27.8 million compared to t

    7/31/24 4:45:00 PM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care

    Vector Group to Host Second Quarter 2024 Results Conference Call

    Vector Group Ltd. (NYSE:VGR) will conduct a conference call and webcast to discuss its second quarter 2024 results on Thursday, August 1, 2024 at 8:00 a.m. (ET). Investors may access the call via live webcast at https://www.webcaster4.com/Webcast/Page/2271/50954. Please join the webcast at least 10 minutes prior to start time. A replay of the call will be available shortly after the call ends on August 1, 2024 through August 15, 2024 at https://www.webcaster4.com/Webcast/Page/2271/50954. Vector Group is a holding company for Liggett Group LLC, Vector Tobacco LLC and New Valley LLC. Additional information concerning the company is available on the Company's website, www.VectorGroupLtd.

    7/25/24 8:00:00 AM ET
    $VGR
    Medicinal Chemicals and Botanical Products
    Health Care